3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
7
Vincristine
6
Cyclophosphamide
5
fludarabine
3
Irinotecan
3
pegfilgrastim
2
irinotecan sucrosofate
2
Zoledronic Acid
2
Vinorelbine
2
Filgrastim
2
Dactinomycin
2
talazoparib
1
silmitasertib
1
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
pazopanib
1
liposomal doxorubicin
1
fludarabine phosphate
1
cabozantinib
1
atezolizumab
1
amino-acid, glucose, and electrolyte solution
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Radiotherapy
1
Mesna
1
Melphalan
1
Influenza Vaccines
1
Indocyanine Green
1
Immunotherapy, Adoptive
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Rhabdomyosarcoma
×
amino-acid, glucose, and electrolyte solution
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled